Pandiani Charlotte, Béranger Guillaume E, Leclerc Justine, Ballotti Robert, Bertolotto Corine
U1065, Institut National de la Santé et de la Recherche Médicale Centre Méditerranéen de Médecine Moléculaire, Université Côte d'Azur, 06200 Nice, France.
Genes Dev. 2017 Apr 15;31(8):724-743. doi: 10.1101/gad.296962.117.
Cutaneous melanoma (CM) and uveal melanoma (UM) derive from cutaneous and uveal melanocytes that share the same embryonic origin and display the same cellular function. However, the etiopathogenesis and biological behaviors of these melanomas are very different. CM and UM display distinct landscapes of genetic alterations and show different metastatic routes and tropisms. Hence, therapeutic improvements achieved in the last few years for the treatment of CM have failed to ameliorate the clinical outcomes of patients with UM. The scope of this review is to discuss the differences in tumorigenic processes (etiologic factors and genetic alterations) and tumor biology (gene expression and signaling pathways) between CM and UM. We develop hypotheses to explain these differences, which might provide important clues for research avenues and the identification of actionable vulnerabilities suitable for the development of new therapeutic strategies for metastatic UM.
皮肤黑色素瘤(CM)和葡萄膜黑色素瘤(UM)分别源自皮肤和葡萄膜黑色素细胞,它们具有相同的胚胎起源并发挥相同的细胞功能。然而,这些黑色素瘤的病因发病机制和生物学行为却大不相同。CM和UM表现出不同的基因改变格局,且具有不同的转移途径和趋向性。因此,过去几年在CM治疗方面取得的治疗进展未能改善UM患者的临床结局。本综述的范围是讨论CM和UM在致瘤过程(病因因素和基因改变)以及肿瘤生物学(基因表达和信号通路)方面的差异。我们提出假设来解释这些差异,这可能为研究途径以及识别适合开发转移性UM新治疗策略的可操作弱点提供重要线索。